Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Lin, CM; Neeru, S; Doufas, AG; Liem, E; Muneer, Shah, Y; Wadhwa, A; Lenhardt, R; Bjorksten, A; Taguchi, A; Kabon, B; Sessler, DI; Kurz, A.
Dantrolene reduces the threshold and gain for shivering.
Anesth Analg. 2004; 98(5):1318-24, table of contents Doi: 10.1213/01.ane.0000108968.21212.d7 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Co-authors Med Uni Graz
Kurz Andrea
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
UNLABELLED: Dantrolene is used for treatment of life-threatening hyperthermia, yet its thermoregulatory effects are unknown. We tested the hypothesis that dantrolene reduces the threshold (triggering core temperature) and gain (incremental increase) of shivering. Healthy volunteers were evaluated on 2 random days: control and dantrolene (approximately 2.5 mg/kg plus a continuous infusion). In Study 1, 9 men were warmed until sweating was provoked and then cooled until arteriovenous shunt constriction and shivering occurred. Sweating was quantified on the chest using a ventilated capsule. Absolute right middle fingertip blood flow was quantified using venous-occlusion volume plethysmography. A sustained increase in oxygen consumption identified the shivering threshold. In Study 2, 9 men were given cold lactated Ringer's solution i.v. to reduce core temperature approximately 2 degrees C/h. Cooling was stopped when shivering intensity no longer increased with further core cooling. The gain of shivering was the slope of oxygen consumption versus core temperature regression. In Study 1, sweating and vasoconstriction thresholds were similar on both days. In contrast, shivering threshold decreased 0.3 +/- 0.3 degrees C, P = 0.004, on the dantrolene day. In Study 2, dantrolene decreased the shivering threshold from 36.7 +/- 0.2 to 36.3 +/- 0.3 degrees C, P = 0.01 and systemic gain from 353 +/- 144 to 211 +/- 93 mL.min(-1).degrees C(-1), P = 0.02. Thus, dantrolene substantially decreased the gain of shivering, but produced little central thermoregulatory inhibition. IMPLICATIONS: Dantrolene substantially decreases the gain of shivering but produces relatively little central thermoregulatory inhibition. It thus seems unlikely to prove more effective than conventional muscle relaxants for treatment of life-threatening hyperthermia.
Find related publications in this database (using NLM MeSH Indexing)
Adolescent - administration & dosage
Adult - administration & dosage
Body Temperature - physiology
Carbon Dioxide - blood
Dantrolene - pharmacology
Heart Rate - drug effects
Hemodynamics - drug effects
Humans - administration & dosage
Male - administration & dosage
Middle Aged - administration & dosage
Muscle Relaxants, Central - pharmacology
Oxygen Consumption - drug effects
Oxyhemoglobins - metabolism
Shivering - drug effects
Skin Temperature - drug effects, physiology
Sweating - drug effects
Vasoconstriction - drug effects

© Med Uni GrazImprint